SCD1 drives bladder cancer progression and trametinib sensitivity

Area of Science:

• Oncology
• Molecular Biology
• Biochemistry

Background:

• Bladder cancer (BCa) remains a significant challenge with limited curative options post-treatment.
• Cancer cells, including BCa, often rely on de novo fatty acid synthesis for growth.
• Stearoyl-CoA desaturase 1 (SCD1) is a key enzyme in fatty acid synthesis and a potential cancer therapeutic target.

Purpose of the Study:

• To investigate the role of SCD1 in bladder cancer.
• To evaluate SCD1 as a prognostic marker and therapeutic target in BCa.
• To explore the association between SCD1 expression and drug sensitivity in BCa.

Main Methods:

• Bioinformatics analysis of public datasets (bulk and single-cell RNA-seq).
• Immunohistochemical examination of bladder cancer tissues.
• Drug sensitivity prediction and validation.

Main Results:

• SCD1 is specifically expressed in BCa cells.
• SCD1 expression correlates with poor tumor grade and prognosis.
• SCD1 enhances the sensitivity of BCa cells to trametinib.

Conclusions:

• SCD1 is a promising biomarker for BCa diagnosis and prognosis.
• Targeting SCD1 may represent a novel therapeutic strategy for bladder cancer.
• SCD1 could aid in optimizing personalized treatment approaches for BCa patients.